References
- Rieger CT, Huppmann S, Peterson L, Rieger H, Ostermann H. Classification of invasive fungal disease in patients with acute myeloid leukemia. Mycoses 2011;54:92–8.
- Raparia K1, Powell SZ, Cernoch P, Takei H. Cerebral mycosis: 7-year retrospective series in a tertiary center. Neuropathology 2010;30:218–23.
- Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996;23:608–15.
- Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis 2011;15;52:e56–93.
- Ruhnke M1, Kofla G, Otto K, Schwartz S. CNS aspergillosis: recognition, diagnosis and management. CNS Drug 2007; 21:659–76.
- Silva-Vergara ML, Rocha IH, Vasconcelos RR, Maltos AL, Neves Fde F, Teixeira Lde A, et al. Central nervous system paracoccidioidomycosis in an AIDS patient: case report. Mycopathologia 2014;177:137–41.
- Nguyen FN, Kar JK, Zakaria A, Schiess MC. Isolated central nervous system histoplasmosis presenting with ischemic pontine stroke and meningitis in an immune-competent patient. JAMA Neurol 2013;70:638–41.
- Zhu L, Weng X, Jin J, Yang F, Li Q, Shi G, et al. Itraconazole injection and oral sequential treatment of cerebral aspergillosis: two cases. Chinese Journal of New Drugs and Clinical 2005;44:938–9.
- Réminiac F, Sonneville R, Massias L, Chochillon C, Wolff M. Very-high dose caspofungin combined with voriconazole to treat central nervous system aspergillosis: substantial penetration of caspofungin into cerebrospinal fluid. Antimicrob Agents Chemother 2014;58:3568–9.